Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside ...

Until recently, the most effective protection against respiratory syncytial virus (RSV) was only available for high-risk infants, and many parents and providers may remember the vulnerability that ...

Knowing patient survival rates is critical to informing research and care delivery, particularly in the oncology space. But what if survival data is inaccurate or incomplete? Well, that could ...

Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs are coming to market faster than ever. A 2024 analysis of drugs included in this ...

With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals. CAMBRIDGE, Mass., Oct. 15, 2025 ...

Healthcare systems worldwide are facing unprecedented pressure, from the rise in chronic diseases and aging populations to fragmented healthcare and over-stretched resources. The result? Delayed, ...

Clinical research is in the midst of a data explosion, and that’s a good thing. Technological advances are enabling access to secure and de-identified data sources for researchers, and the ...

Forbes contributors publish independent expert analyses and insights. Gary Drenik is a writer covering AI, analytics and innovation. As of 2023, the pharmaceutical industry has boosted its ad spending ...

Patients with early Alzheimer’s disease (AD) who initiated lecanemab treatment at a specialty memory clinic showed an expected and manageable side-effect profile, new research showed. “The findings ...

Echoing President Donald Trump’s call to accelerate medical innovation, Food and Drug Administration (FDA) Commissioner Marty Makary announced that the agency will no longer block companies from ...

Randomized trials provide high-quality, internally consistent data on selected clinical questions, but lack generalizability for the aging population who are most often diagnosed with cancer and have ...